Dr. Ahmed Kaseb, MD

• Medical Oncology

• Internal Medicine

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Kasr El Aini College Of Medicine / University Of Cairo

  Medical School, 1996

• Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination, 2022-11-21

• Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma, 2017-06-01

• A machine learning model to predict hepatocellular carcinoma response to transcatheter arterial chemoembolization, 2019-09-25

• A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of ThymoQuinone Formula (TQF) for Treating Outpatient SARS-CoV-2, 2022-05-07

• Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma, 2022-04-09

• The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression on the Incidence and Severity of COVID-19 Infection, 2021-03-22

• Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+T-cell lymphoma, 2023-06-13

• Validation of an IGF-CTP scoring system for assessing hepatic reserve in egyptian patients with hepatocellular carcinoma, 2015-05-19

• Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials, 2015-06-23

• Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing, 2014-02-21

• Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers, 2016-12-12

• Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma, 2016-09-16

• Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+T-cell lymphoma, 2019-07-24

• Validation of a preclinical model of diethylnitrosamine-induced hepatic neoplasia in Yucatan miniature pigs, 2016-06-16

• Multimodality annotated hepatocellular carcinoma data set including pre- and post-TACE with imaging segmentation, 2023-01-18

• Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View, 2022-03-30

• The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma, 2023-10-07

• Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma, 2022-10-06

• Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma, 2019-01-16

• Modified Cisplatin/Interferon a-2b/Doxorubicin/Fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability and survival of initially unresectable hepatocellular carcinoma, 2013-07-02

• Dietary Patterns and Hepatocellular Carcinoma Risk among US Adults, 2021-06-11

• NATURAL HISTORY OF T1N0M0 HEPATOCELLULAR CARCINOMA: LARGE SCALE STUDY IN THE UNITED STATES, 2017-07-06

• HER2/neu-directed therapy for biliary tract cancer, 2015-05-29

• Impact of Integrating IGF-1 Levels Into MELD Score for Survival Prediction in Hepatocellular Carcinoma Patients, 2020-10-07

• The transcription factors Ik-1 and MZF1 downregulateIGF-IRexpression in NPM-ALK+T-cell lymphoma, 2015-02-25

• Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors, 2023-02-14

• Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma, 2019-07-09

• Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy, 2016-08-31

• Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab, 2021-07-29

• Type I insulin-like growth factor receptor signaling in hematological malignancies, 2016-09-19

• Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers, 2022-12-03

• Origin and role of hepatic myofibroblasts in hepatocellular carcinoma, 2020-03-31

• Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA, 2019-07-30

• Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib, 2021-04-13

• Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients, 2022-12-06

• Bayesian Edge Regression in Undirected Graphical Models to Characterize Interpatient Heterogeneity in Cancer, 2022-01-05

• Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma, 2020-09-24

• Perioperative Nivolumab Monotherapy versus Nivolumab Plus Ipilimumab in Resectable Hepatocellular Carcinoma: a randomised, open-label, phase 2 trial, 2022-01-20

• Dietary N-Nitroso Compounds and Risk of Hepatocellular Carcinoma: A US-Based Study, 2021-08-26